Synteract acquired Cu-Tech a dermatology specialist CRO. The two companies have now created a dedicated center of dermatology development.
Cu-Tech is a dermatology CRO with more than two decades of experience, having managed 130+ dermatology trials. The New Jersey-based CRO is known for its relationships with its clients and investigative sites, as well as for its knowledge in working across a variety of dermatological indications.
“The acquisition of Cu-Tech represents the next step in our strategy to specialize in targeted areas of clinical development,” Steve Powell, CEO of Synteract, said. “We have combined Synteract’s existing base of experience in dermatology with the focused strength and expertise that Cu-Tech has provided its customers for over 20 years. Dermatology is poised for continued strong growth, and in acquiring Cu-Tech, we have created a leading CRO for dermatological services and site connections. In recognition of their leadership in the dermatology sector, we will support the Cu-Tech team in their current form. Dermatology is now our fifth specialized area of focus, alongside oncology, neuro degenerative diseases, rare and orphan diseases, and pediatrics.”
With over 120 dermatologic trials conducted including more than 17,000 patients, Synteract draws on a longstanding dedication to dermatological drug development in complex Phase I-IV clinical trials. By adding a center of development in dermatology, Synteract has positioned itself to better meet sponsors’ specific needs, including addressing stringent trial demands, delivering consistency of study conduct across investigational sites and ensuring accuracy in reporting. Synteract brings international delivery capabilities to the relationship with Cu-Tech as well as specific services in feasibility, biostatistics, clinical operations, data management, medical writing and regulatory expertise.